Latest Osteopore (ASX:OSX) News

A single diagnostics update sparked a breakout week, while a handful of biotech names sold off hard despite busy newsflow. Capital raisings, takeover steps and US market pushes kept healthcare in motion heading into mid-February milestones.

Osteopore Limited has successfully raised the entire $5 million from the first tranche of its $20 million convertible notes issuance, securing funds to support ongoing operations and future growth.

Osteopore Limited reported a 30% year-on-year revenue increase in Q4 CY25, overcoming a slowdown in South Korea, and secured a strategic five-year partnership with DKSH Malaysia to expand its dental product reach.

A small-cap healthcare rally had a clear centre: distribution deals, US regulatory steps, and big cheques. Osteopore, Echo IQ and Anteris led the week, while a handful of names slipped despite solid operational updates.

Osteopore Limited has secured an exclusive agreement with MontsMed Hong Kong to introduce its innovative 3D-printed orthopaedic implants into Hong Kong, positioning itself strategically within the Greater Bay Area’s burgeoning medical market.

Osteopore Limited has inked a three-year exclusive distribution agreement with MontsMed to introduce its advanced orthopaedic trauma reconstruction products into Hong Kong, positioning itself strategically within the Greater Bay Area.

A few stocks did the heavy lifting this week, with one biotech exploding higher and a gas name collapsing on the other side of the ledger. Big moves came from capital raises, regulator decisions, and drill results that investors treated as near-term value, not distant promises.

Osteopore Limited has inked an exclusive collaboration with Majeton to commercialise its cutting-edge 3D-printed bioresorbable implants across China, Hong Kong, and Macau, unlocking significant growth potential in the region.

Osteopore Limited has secured an exclusive multi-year distribution agreement with Majeton to commercialise its dental and maxillofacial products in China, Hong Kong, and Macau, marking a major step in its Asia-Pacific expansion.

Osteopore Limited has completed the full subscription of Tranche 1 under its A$20 million convertible notes facility, raising an additional A$250,000 to support ongoing business and future projects.

Osteopore Limited has drawn an additional A$250,000 under the first tranche of its redeemable convertible notes, continuing its steady capital raise to support growth and innovation.

Osteopore Limited has partnered with DKSH Malaysia in a five-year agreement to distribute its innovative dental products, aiming to capture significant growth in Malaysia’s guided bone regeneration sector.